OrbiMed’s Regulus Therapeutics RGLS Stock Holding History

OrbiMed’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3,333	Closed	-$6.42M	–	141
2014 Q4	$6.42M	Buy	+3,333	New	+$5.93M	0.06%	108

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed's RGLS Position: Q1 2015 in Review

OrbiMed sold out of Regulus Therapeutics (RGLS) in Q1 2015, closing a stake of 3,333 shares — an estimated $6.42M sold.

OrbiMed first reported a position in RGLS in Q4 2014 and held it in 1 quarter. The position peaked at $6.42M in Q4 2014. 88 funds tracked by Wall St. Rank hold RGLS as of Q1 2015.

OrbiMed reported no remaining Regulus Therapeutics position as of Q1 2015 after selling out during the quarter.
OrbiMed sold 3,333 Regulus Therapeutics shares in Q1 2015, an estimated $6.42M.
OrbiMed first reported a position in Regulus Therapeutics in Q4 2014 and held it in 1 quarter.
OrbiMed's Regulus Therapeutics position peaked at $6.42M in Q4 2014.
88 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2015.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.